Ellen W. Seely

Ellen W. Seely

Auto-generated profile, based on publicly available information

Ellen W. Seely

Endocrinology, Diabetes and Hypertension Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (E.W.S.)

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SBSuzanne D. Burke
Suzanne D. Burke
ZZZsuzsanna Kinga Zsengeller
Zsuzsanna Kinga Zsengeller
EKEliyahu V. Khankin
Eliyahu V. Khankin
ALAgnes S. Lo
Agnes S. Lo
ARAugustine Rajakumar
Augustine Rajakumar
SKS. Ananth Karumanchi
S. Ananth Karumanchi
Preeclampsia is a hypertensive disorder of pregnancy in which patients develop profound sensitivity to vasopressors, such as angiotensin II, and is associated with substantial morbidity for the mother and fetus. Enhanced vasoconstrictor sensitivity and elevations in soluble fms-like tyrosine kinase 1 (sFLT1), a circulating antiangiogenic protein, precede clinical signs and symptoms of preeclampsia. Here, we report that overexpression of sFlt1 in pregnant mice induced angiotensin II sensitivity and hypertension by impairing endothelial nitric oxide synthase (eNOS) phosphorylation and promoting oxidative stress in the vasculature. Administration of the NOS inhibitor l-NAME to pregnant mice recapitulated the angiotensin sensitivity and oxidative stress observed with sFlt1 overexpression. Sildenafil, an FDA-approved phosphodiesterase 5 inhibitor that enhances NO signaling, reversed sFlt1-induced hypertension and angiotensin II sensitivity in the preeclampsia mouse model. Sildenafil treatment also improved uterine blood flow, decreased uterine vascular resistance, and improved fetal weights in comparison with untreated sFlt1-expressing mice. Finally, sFLT1 protein expression inversely correlated with reductions in eNOS phosphorylation in placental tissue of human preeclampsia patients. These data support the concept that endothelial dysfunction due to high circulating sFLT1 may be the primary event leading to enhanced vasoconstrictor sensitivity that is characteristic of preeclampsia and suggest that targeting sFLT1-induced pathways may be an avenue for treating preeclampsia and improving fetal outcomes.

5 September 2017 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
WMWorapaka Manosroi
Worapaka Manosroi
JTJia Wei Tan
Jia Wei Tan
CRChevon M Rariy
Chevon M Rariy
BSBei Sun
Bei Sun
MGMark O Goodarzi
Mark O Goodarzi
ESEllen W Seely
Ellen W Seely
Context Hypertension in young women is uncommon compared to young men and older women. Estrogen appears to protect most women against hypertension with incidence increasing after menopause. Since some premenopausal women develop hypertension, estrogen may play a different role in these women. Genetic variations in the estrogen receptor (ER) are associated with cardiovascular disease. ER-β, encoded by ESR2, is the ER predominantly expressed in vascular smooth muscle. Objective To determine an association of single nucleotide polymorphisms (SNPs) in ESR2 with salt-sensitivity of blood pressure (SSBP) and estrogen status in women. Methods Candidate gene association study with ESR2 and SSBP conducted in normotensive and hypertensive women and men in 2 cohorts: 1) International Hypertensive Pathotype (HyperPATH) (n=584) (discovery) and Mexican-American Hypertension-Insulin Resistance (HTN-IR) (n=662) (validation). SNPs in ESR1 (ER-α) were also analyzed. Analysis conducted in younger (< 51 years, premenopausal, “estrogen-replete”) and older women (≥51 years, postmenopausal, “estrogen-deplete”). Men analyzed to control for aging. Results Multivariate analyses of HyperPATH data between variants of ESR2 and SSBP documented that ESR2 rs10144225 minor (risk) allele carriers had a significantly positive association with SSBP driven by estrogen-replete women (β =+4.4 mmHg per risk allele, P=0.004). Findings were confirmed in HTN-IR premenopausal women. HyperPATH cohort analyses revealed risk allele carriers versus non-carriers had increased aldosterone/renin ratios. No associations were detected with ESR1. Conclusions The variation at rs10144225 in ESR2 was associated with SSBP in premenopausal women (estrogen-replete) and not in men or postmenopausal women (estrogen-deplete). Inappropriate aldosterone levels on liberal salt diet may mediate the SSBP.

29 July 2024 in Endocrinology and Metabolism Clinics of North America
Verified
Journal Article
Closed access
EREmily A. Rosenberg
Emily A. Rosenberg
ESEllen W. Seely
Ellen W. Seely

4 March 2021 in Journal of Women's Health
Verified
Journal Article
Closed access
ESEllen W. Seely
Ellen W. Seely
ACAnn C. Celi
Ann C. Celi
JCJaimie Chausmer
Jaimie Chausmer
CGCornelia Graves
Cornelia Graves
SKSarah Kilpatrick
Sarah Kilpatrick
JRJanet W. Rich-Edwards
Janet W. Rich-Edwards
Background: Preeclampsia predicts future cardiovascular disease (CVD) yet few programs exist for post-preeclampsia care. Methods: The Health after Preeclampsia Patient and Provider Engagement Network workshop was convened at the Radcliffe Institute for Advanced Study in June 2018. The workshop sought to identify: 1) patient perspectives on barriers and facilitators to CVD risk reduction; 2) clinical programs specialized in post-preeclampsia care; 3) recommendations by national organizations for risk reduction; and 4) next steps. Stakeholders included the Preeclampsia Foundation, patients, clinicians who had initiated CVD risk reduction programs for women with prior preeclampsia, researchers, and national task force members. Results: Participants agreed there is insufficient awareness and action to prevent CVD after preeclampsia. Patients suggested a clinician checklist to ensure communication of CVD risks, enhanced training for clinicians on the link between preeclampsia and CVD, and a post-delivery appointment with a clinician knowledgeable about this link. Clinical programs primarily served patients in the first postpartum year, bridging obstetrical and primary care. They recommended CVD risk modification with periodic blood pressure, weight, lipid and diabetes screening. Barriers included the paucity of programs designed for this population and gaps in insurance coverage after delivery. The American Heart Association, the American College of Obstetricians and Gynecologists, and the Preeclampsia Foundation have developed guidelines and materials for patients and providers to guide management of women with prior preeclampsia. Conclusions: Integrated efforts of patients, caregivers, researchers, and national organizations are needed to improve CVD prevention after preeclampsia. This meeting's recommendations can serve as a resource and catalyst for this effort.

31 December 2020 in JMIR Formative Research
Verified
Journal Article
Open access
ESEllen W Seely
Ellen W Seely
PWPatricia Flynn Weitzman
Patricia Flynn Weitzman
DCDharma Cortes
Dharma Cortes
SVSara Romero Vicente
Sara Romero Vicente
SLSue E Levkoff
Sue E Levkoff
Background: Hispanic women have increased risk of gestational diabetes mellitus (GDM), which carries an increased risk for future type 2 diabetes, compared to non-Hispanic women. In addition, Hispanic women are less likely to engage in healthy eating and physical activity, which are both risk factors for type 2 diabetes. Supporting patients to engage in healthy lifestyle behaviors through mobile health (mHealth) interventions is increasingly recognized as a viable, underused tool for disease prevention, as they reduce barriers to access frequently experienced in face-to-face interventions. Despite the high percentage of smartphone ownership among Hispanics, mHealth programs to reduce risk factors for type 2 diabetes in Hispanic women with prior GDM are lacking. Objective: This study aimed to (1) develop a mobile app (¡Hola Bebé, Adiós Diabetes!) to pilot test a culturally tailored, bilingual (Spanish/English) lifestyle program to reduce risk factors for type 2 diabetes in Hispanic women with GDM in the prior 5 years; (2) examine the acceptability and usability of the app; and (3) assess the short-term effectiveness of the app in increasing self-efficacy for both healthy eating and physical activity, and in decreasing weight. Methods: Social cognitive theory provided the framework for the study. A prototype app was developed based on prior research and cultural tailoring of content. Features included educational audiovisual modules on healthy eating and physical activity; personal action plans; motivational text messages; weight tracking; user-friendly, easy-to-follow recipes; directions on building a balanced plate; and tiered badges to reward achievements. Perceptions of the app’s acceptability and usability were explored through four focus groups. Short-term effectiveness of the app was tested in an 8-week single group pilot study. Results: In total, 11 Hispanic women, receiving care at a federally qualified community health center, aged 18-45 years, and with GDM in the last 5 years, participated in four focus groups to evaluate the app’s acceptability and usability. Participants found the following sections most useful: audiovisual modules, badges for completion of activities, weight-tracking graphics, and recipes. Suggested modifications included adjustments in phrasing, graphics, and a tiering system of badges. After app modifications, we conducted usability testing with 4 Hispanic women, with the key result being the suggestion for a “how-to tutorial.” To assess short-term effectiveness, 21 Hispanic women with prior GDM participated in the pilot. There was a statistically significant improvement in both self-efficacy for physical activity (P=.003) and self-efficacy for healthy eating (P=.007). Weight decreased but not significantly. Backend process data revealed a high level of user engagement. Conclusions: These data support the app’s acceptability, usability, and short-term effectiveness, suggesting that this mHealth program has the potential to fill the gap in care experienced by Hispanic women with prior GDM following pregnancy. Future studies are needed to determine the effectiveness of an enhanced app in a randomized controlled trial. Trial Registration: ClinicalTrials.gov NCT04149054; https://clinicaltrials.gov/ct2/show/NCT04149054

3 March 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
RBRianne C Bijl
Rianne C Bijl
SBSophie E Bangert
Sophie E Bangert
RSRaj Shree
Raj Shree
ABAlina N Brewer
Alina N Brewer
NANorlisa Abrenica-Keffer
Norlisa Abrenica-Keffer
ESEllen W Seely
Ellen W Seely
Objectives To gain insight into the patient journey through a pre-eclampsia-complicated pregnancy. Design Cross-sectional patient registry study. Setting Online patient registry initiated by the Preeclampsia Foundation. Participants Women with a history of pre-eclampsia enrolled in The Preeclampsia Registry (TPR). Primary and secondary outcome measures Retrospective patient-reported experience measures concerning awareness of pre-eclampsia, timing and type of information on pre-eclampsia received, involvement in decision making regarding medical care, mental/emotional impact of the pre-eclampsia-complicated pregnancy and impact on future pregnancy planning. Results Of 3618 TPR-participants invited to complete the Patient Journey questionnaire, data from 833 (23%) responders were available for analysis. Most responders were white (n=795, 95.4%) and lived in the USA (n=728, 87.4%). Before their pre-eclampsia diagnosis, 599 (73.9%) responders were aware of the term ‘pre-eclampsia’, but only 348 (43.7%) were aware of its associated symptoms. Women with a lower level of education were less likely to have heard of pre-eclampsia (OR 0.36, 95% CI 0.21 to 0.62). Around the time of diagnosis, 29.2% of responders did not feel involved in the decision making, which was associated with reporting a serious mental/emotional impact of the pre-eclampsia experience (OR 2.46, 95% CI 1.58 to 3.84). Over time, there was an increase in the proportion of women who were aware of the symptoms of pre-eclampsia (32.2% before 2011 to 52.5% after 2016; p<0.001) and in the proportion of responders stating they received counselling about the later-life health risks associated with pre-eclampsia (14.2% before 2011 to 25.6% after 2016; p=0.005). Conclusions This study demonstrates that improved patient education regarding pre-eclampsia is needed, that shared decision making is of great importance to patients to enhance their healthcare experience, and that healthcare providers should make efforts to routinely incorporate counselling about the later-life health risks associated with pre-eclampsia. Trial registration number NCT02020174.